Ryuji Tabata
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ryuji Tabata has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
Hiroshi Sasaki
Department of Urology, The Jikei University School of Medicine
2 shared publicationsHiroyuki Takahashi
Department of Pathology, The Jikei University School of Medicine
2 shared publicationsShin Egawa
Department of Urology, The Jikei University School of Medicine
2 shared publications- Takahiro Kimura
Department of Urology The Jikei University School of Medicine Tokyo Japan
2 shared publications - Chikara Ohyama
Department of Advanced Transplant and Regenerative Medicine, Hirosaki University Graduate School of Medicine, Hirosaki, Japan
1 shared publication - Daisuke Noro
Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan
1 shared publication
Latest Publications
- 8 July 2025
- Published by Springer Nature in International Journal of Clinical Oncology
- Vol. 30 (9) , 1858-1865
Real-world trends in the use and outcomes of novel androgen receptor signaling inhibitor therapy in patients with non-metastatic castration-resistant prostate cancer: a multicenter retrospective study
Background Although three phase III trials demonstrated significant oncological benefits of novel androgen receptor signaling inhibitors (ARSIs) in patients with non-metastatic castration-resistant prostate cancer (nmCRPC), trends in novel ARSI use have been sparsely documented. Moreover, the safety and oncological benefits of novel ARSIs in real-world nmCRPC settings remain unclear. Methods This multicenter retrospective study evaluated 318 consecutive patients with nmCRPC treated between 2001 and 2024. Trends in the use of novel ARSIs were analyzed. Adverse events associated with novel ARSIs were assessed using the Common Terminology Criteria for Adverse Events version 5.0. Multivariable Cox proportional hazards regression analyses were conducted to evaluate the effects of novel ARSIs on metastasis-free survival (MFS) and overall survival (OS). Results The median age and follow-up period after nmCRPC diagnosis were 77 years and 46 months, respectively. Of the 318 patients, 231 (73%) received novel ARSI treatment at some point during nmCRPC management. First-line use of novel ARSIs gradually increased following their initial approval for nmCRPC in 2014. The rate of first-line novel ARSI use was significantly higher in 2020–2024 than in 2014–2019 (68% vs. 33%, P < 0.001). The incidence rates of any-grade and grade ≥ 3 adverse events associated with novel ARSIs were 23% and 2.2%, respectively. After adjusting for confounding variables, novel ARSIs were independently and significantly associated with prolonged MFS and OS. Conclusions Novel ARSIs have become a primary treatment strategy for nmCRPC in real-world settings, demonstrating both safety and significant oncological benefits.
- 8 July 2025
- Published by Springer Nature in International Journal of Clinical Oncology
- Vol. 30 (9) , 1858-1865
Real-world trends in the use and outcomes of novel androgen receptor signaling inhibitor therapy in patients with non-metastatic castration-resistant prostate cancer: a multicenter retrospective study
Background Although three phase III trials demonstrated significant oncological benefits of novel androgen receptor signaling inhibitors (ARSIs) in patients with non-metastatic castration-resistant prostate cancer (nmCRPC), trends in novel ARSI use have been sparsely documented. Moreover, the safety and oncological benefits of novel ARSIs in real-world nmCRPC settings remain unclear. Methods This multicenter retrospective study evaluated 318 consecutive patients with nmCRPC treated between 2001 and 2024. Trends in the use of novel ARSIs were analyzed. Adverse events associated with novel ARSIs were assessed using the Common Terminology Criteria for Adverse Events version 5.0. Multivariable Cox proportional hazards regression analyses were conducted to evaluate the effects of novel ARSIs on metastasis-free survival (MFS) and overall survival (OS). Results The median age and follow-up period after nmCRPC diagnosis were 77 years and 46 months, respectively. Of the 318 patients, 231 (73%) received novel ARSI treatment at some point during nmCRPC management. First-line use of novel ARSIs gradually increased following their initial approval for nmCRPC in 2014. The rate of first-line novel ARSI use was significantly higher in 2020–2024 than in 2014–2019 (68% vs. 33%, P < 0.001). The incidence rates of any-grade and grade ≥ 3 adverse events associated with novel ARSIs were 23% and 2.2%, respectively. After adjusting for confounding variables, novel ARSIs were independently and significantly associated with prolonged MFS and OS. Conclusions Novel ARSIs have become a primary treatment strategy for nmCRPC in real-world settings, demonstrating both safety and significant oncological benefits.
- 1 January 2017
- Published by Japanese Urological Association in The Japanese Journal of Urology
- Vol. 108 (2) , 87-95
EXPRESSION OF PLAKIN FAMILY IN UROTHELIAL CARCINOMA OF THE UPPER URINARY TRACT
(目的)本研究は上部尿路癌におけるペリプラキンおよび他のプラキンファミリー蛋白の発現変化を検討し,臨床病理学的因子との関係を解明することを目的とした. (対象と方法)2000年4月から2005年12月に,東京慈恵会医科大学泌尿器科にて手術を受けた上部尿路上皮癌(腎盂癌および尿管癌)患者57名を対象とした.癌部および非癌部におけるペリプラキン,エンボプラキン,プレクチン,デスモプラキンの発現を免疫組織染色にて解析し,臨床像と比較検討した. (結果)上部尿路癌組織におけるペリプラキン発現は,正常尿路上皮に比べ,強陽性を示す割合は有意に低下していた(P<0.0001).またエンボプラキンおよびデスモプラキンの発現も,強陽性を示す割合は癌部で有意に低下していた(それぞれP<0.0001).カプラン・マイヤー法およびログランク検定を用いた検討では,ペリプラキンとエンボプラキンの発現は予後と有意な相関を認めなかったが,デスモプラキンの強発現は癌特異生存率および全生存率が有意に低く(P=0.023および0.034),プレクチンの強発現は非転移生存率が有意に低かった(P=0.034). (結論)上部尿路上皮癌において,プラキンファミリー,特にデスモプラキンは予後予測マーカーとなる可能性が示唆された.
- 1 January 2017
- Published by Japanese Urological Association in The Japanese Journal of Urology
- Vol. 108 (2) , 87-95
EXPRESSION OF PLAKIN FAMILY IN UROTHELIAL CARCINOMA OF THE UPPER URINARY TRACT
(目的)本研究は上部尿路癌におけるペリプラキンおよび他のプラキンファミリー蛋白の発現変化を検討し,臨床病理学的因子との関係を解明することを目的とした. (対象と方法)2000年4月から2005年12月に,東京慈恵会医科大学泌尿器科にて手術を受けた上部尿路上皮癌(腎盂癌および尿管癌)患者57名を対象とした.癌部および非癌部におけるペリプラキン,エンボプラキン,プレクチン,デスモプラキンの発現を免疫組織染色にて解析し,臨床像と比較検討した. (結果)上部尿路癌組織におけるペリプラキン発現は,正常尿路上皮に比べ,強陽性を示す割合は有意に低下していた(P<0.0001).またエンボプラキンおよびデスモプラキンの発現も,強陽性を示す割合は癌部で有意に低下していた(それぞれP<0.0001).カプラン・マイヤー法およびログランク検定を用いた検討では,ペリプラキンとエンボプラキンの発現は予後と有意な相関を認めなかったが,デスモプラキンの強発現は癌特異生存率および全生存率が有意に低く(P=0.023および0.034),プレクチンの強発現は非転移生存率が有意に低かった(P=0.034). (結論)上部尿路上皮癌において,プラキンファミリー,特にデスモプラキンは予後予測マーカーとなる可能性が示唆された.
- Open Access
- 25 July 2016
- Published by Wiley in Cancer Medicine
- Vol. 5 (9) , 2314-2322
Do androgen deprivation and the biologically equivalent dose matter in low‐dose‐rate brachytherapy for intermediate‐risk prostate cancer?
The objective of this study was to investigate the impact of the biologically equivalent dose (BED) on treatment outcomes after iodine‐125 low‐dose‐rate brachytherapy (LDR‐BT) with or without supplemental external beam radiotherapy (EBRT) and androgen deprivation therapy (ADT) for intermediate‐risk prostate cancer (PCa). We retrospectively evaluated 292 Japanese patients. The impact of the BED and ADT on treatment outcomes was investigated. Cox proportional hazard models were used for univariate and multivariate analysis with biological progression‐free survival (bPFS) and clinical progression‐free survival (cPFS) as the primary outcome measures. The median follow‐up was 66 months. The bPFS and cPFS rates at 5‐/7‐years were 91.6/87.7% and 95.9/94.0%, respectively. When stratified by BED levels, the bPFS rates at 5‐/7‐years were 92.1/89.3% for 0.05). Based on ADT duration, the bPFS rates at 5‐/7‐years were 89.8/83.5%, 89.7/89.7%, and 97.5/97.5% for none, 1–3 months, and 4–12 months, respectively (P = 0.03). For the univariate analysis, the use of ADT and its duration were significant predictors for bPFS, whereas BED was not significant. A multivariate analysis did not indicate the use of ADT itself was significant, however, when covariates were accounted for by the duration of ADT, the longer use of ADT was found to significantly improve bPFS. Although cPFS was associated neither with the BED levels nor ADT duration (P > 0.05), ADT duration had a trend of improving cPFS (P = 0.053). The higher levels of BED did not significantly impact bPFS for intermediate‐risk PCa after LDR‐BT with or without supplemental EBRT and ADT. The longer duration of ADT could provide an additional benefit in the context of high‐dose irradiation generated by LDR‐BT.
- 25 July 2016
- Published by Wiley in Cancer Medicine
- Vol. 5 (9) , 2314-2322
Open AccessDo androgen deprivation and the biologically equivalent dose matter in low‐dose‐rate brachytherapy for intermediate‐risk prostate cancer?
The objective of this study was to investigate the impact of the biologically equivalent dose (BED) on treatment outcomes after iodine‐125 low‐dose‐rate brachytherapy (LDR‐BT) with or without supplemental external beam radiotherapy (EBRT) and androgen deprivation therapy (ADT) for intermediate‐risk prostate cancer (PCa). We retrospectively evaluated 292 Japanese patients. The impact of the BED and ADT on treatment outcomes was investigated. Cox proportional hazard models were used for univariate and multivariate analysis with biological progression‐free survival (bPFS) and clinical progression‐free survival (cPFS) as the primary outcome measures. The median follow‐up was 66 months. The bPFS and cPFS rates at 5‐/7‐years were 91.6/87.7% and 95.9/94.0%, respectively. When stratified by BED levels, the bPFS rates at 5‐/7‐years were 92.1/89.3% for 0.05). Based on ADT duration, the bPFS rates at 5‐/7‐years were 89.8/83.5%, 89.7/89.7%, and 97.5/97.5% for none, 1–3 months, and 4–12 months, respectively (P = 0.03). For the univariate analysis, the use of ADT and its duration were significant predictors for bPFS, whereas BED was not significant. A multivariate analysis did not indicate the use of ADT itself was significant, however, when covariates were accounted for by the duration of ADT, the longer use of ADT was found to significantly improve bPFS. Although cPFS was associated neither with the BED levels nor ADT duration (P > 0.05), ADT duration had a trend of improving cPFS (P = 0.053). The higher levels of BED did not significantly impact bPFS for intermediate‐risk PCa after LDR‐BT with or without supplemental EBRT and ADT. The longer duration of ADT could provide an additional benefit in the context of high‐dose irradiation generated by LDR‐BT.